中恒集團(600252.SH):血栓通在二級以下的基層醫療機構佔據公司該產品銷售超過30%的市場份額
格隆匯9月14日丨中恒集團(600252.SH)在9月12日投資者關係活動上表示,公司正在積極推進血栓通二級以下醫療機構解限工作,具體時間暫無法確定。公司血栓通在二級以下的基層醫療機構佔據公司該產品銷售超過30%的市場份額,若能實現血栓通在基層醫療機構報銷,血栓通在基層醫療機構的銷售將得到恢復。我們將積極推動血栓通在基層醫療機構的銷售,通過合法合規的推廣去提升市場佔有率,未來銷售有望得到進一步提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.